Therapeutic Advances in Relapsed/Refractory DLBCL: A Focus on Newly Available Treatment Strategies
_____ is the target of an antibody-drug conjugate that was recently approved in combination with chemotherapy for relapsed/refractory diffuse large B-cell lymphoma.(1,2)
To hear expert perspectives and learn more about key clinical data regarding the evolving treatment strategies for patients with DLBCL, click the “Continue” button.
- Polatuzumab vedotin-piiq [package insert]. 2019.
- Sehn LH, et al. J Clin Oncol. 2019. [Epub ahead of print].
Christopher Flowers, MD
Department of Lymphoma/Myeloma
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Jia Ruan, MD, PhD
Associate Professor of Clinical Medicine
Division of Hematology and Medical Oncology
Weill Cornell Medical College
New York, NY
Amy Burdette, PhD
Manager, Educational Strategy & Content
Rebecca L. Julian, MS, ELS
Senior Manager, Editorial
Kathryn Schaefer, MSN, RN, CPHRM
Senior Manager, Accreditation and Compliance
East Lansing, MI
Haifa Kassis, MD
Upon completion, participants should be able to:
- Consider existing and emerging clinical research data in the formulation of therapeutic recommendations for patients with relapsed/refractory DLBCL
This activity is intended for hematologists/oncologists, oncology nurses, and other healthcare professionals who work in community cancer centers.
Statement of Need
DLBCL is the most common aggressive lymphoma in the United States, accounting for nearly 30% of new cases of non-Hodgkin lymphoma (NHL). Survival outcomes in DLBCL have improved significantly in the last several decades due to therapeutic advances. Despite these gains, however, advanced-stage DLBCL is essentially incurable, as most patients eventually experience relapse or become refractory to treatment. Thus, prognosis among this patient population remains poor. After disease progression, a sizable percentage of patients are not eligible for an autologous stem cell transplantation (ASCT), and prognosis is even worse among patients whose disease relapses following ASCT. No standard of care exists for salvage therapy in DLBCL; therefore, the management of relapsed/refractory disease presents a significant challenge to hematologists/oncologists. The recent approvals of novel agents, along with more agents under clinical investigation, offer the potential to improve outcomes in this difficult-to-treat patient population. However, managing this malignancy is now substantially more complex, as the new treatment options call into question traditional therapies and algorithms that have guided management for many years. In addition, staying current on new developments, approvals, and recommendations is critical to enable the rapid incorporation and safe use of these therapies in clinical practice as they become available.
Provided by Med-IQ.
Med-IQ is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Med-IQ designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Med-IQ is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.
This nursing activity has been approved for up to 0.25 contact hour.
Medium/Method of Participation
This CME activity consists of a 0.25-credit online publication. To receive credit, read the introductory CME material, read the publication, and complete the post-survey, evaluation, attestation, and post-test, answering at least 70% of the post-test questions correctly.
Initial Release Date: February 6, 2020
Expiration Date: February 5, 2021
Estimated Time to Complete This Activity: 15 minutes
Med-IQ requires any person in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as those in any amount occurring within the past 12 months, including those of a spouse/life partner, that could create a conflict of interest (COI). Individuals who refuse to disclose will not be permitted to contribute to this CME activity in any way. Med-IQ has policies in place that will identify and resolve COIs prior to this educational activity. Med-IQ also requires faculty to disclose discussions of investigational products or unlabeled/unapproved uses of drugs or devices regulated by the US Food and Drug Administration.
The content of this activity has been peer reviewed and has been approved for compliance. The faculty and contributors have indicated the following financial relationships, which have been resolved through an established COI resolution process, and have stated that these reported relationships will not have any impact on their ability to give an unbiased presentation.
Christopher Flowers, MD
Consulting fees/advisory boards: BeiGene, Celgene Corporation, Denovo Biopharma
Jia Ruan, MD, PhD
Consulting fees/advisory boards: Celgene Corporation, Kite Pharma
Contracted research: AstraZeneca, Celgene Corporation, Pharmacyclics LLC, Seattle Genetics
The writer, peer reviewers, and activity planners have no financial relationships to disclose.
Statement of Evidence-Based Content
Educational activities that assist physicians in carrying out their professional responsibilities more effectively and efficiently are consistent with the ACCME definition of continuing medical education (CME). As an ACCME-accredited provider of CME, Med-IQ has a policy to review and ensure that all the content and any recommendations, treatments, and manners of practicing medicine in CME activities are scientifically based, valid, and relevant to the practice of medicine. Med-IQ is responsible for validating the content of the CME activities it provides. Specifically, (1) all recommendations addressing the medical care of patients must be based on evidence that is scientifically sound and recognized as such within the profession; (2) all scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to generally accepted standards of experimental design, data collection, and analysis.
Med-IQ is not liable for any decision made or action taken in reliance upon the information provided through this activity.
For questions or comments about this activity, please contact Med-IQ. Call (toll-free) 866 858 7434 or email firstname.lastname@example.org.
Operating system - Med-IQ supports the following operating systems:
- Microsoft Windows supported by Microsoft
- Mac OS supported by Apple
Browsers - Med-IQ supports the current version of each browser listed below, plus two prior versions:
Microsoft Internet Explorer
- Microsoft Edge
Operating system - Med-IQ supports the current operating system, plus two prior releases:
- Android (eg, Samsung Galaxy)
- Apple (eg, iPhone/iPad)
Browsers - Med-IQ supports the default browser for the applicable operating system release, plus two prior releases:
- Android (Chrome)
- Apple (Safari)
Applications & Software
PDF Viewer - Adobe Acrobat Reader or Adobe Reader
Adobe Flash Player - Med-IQ supports the current version, plus two prior versions
For technical assistance, please refer to our Support Manual.
The information provided through this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.
Privacy & Confidentiality
Acknowledgment of Commercial Support
This activity is supported by an educational grant from Genentech.
© 2020 Med-IQ, Inc.
Unless otherwise indicated, photographed subjects who appear within the content of this activity or on artwork associated with this activity are models; they are not actual patients or doctors.